Speakers
Dr Derek Connolly Consultant Cardiologist at Birmingham City Hospital, Birmingham
Dr Dermot Neely Retired Lipidologist, HEART UK Trustee
Learning objectives
- Triglycerides as a target for treatment
- How treatment can improve outcomes
- The role of highly-purified omega-3 fatty acid (icosapent ethyl) to treat hypertriglyceridaemia
- Early versus later omega-3 fatty acid studies
- REDUCE-IT – randomised, double-blind, placebo-controlled trial looking at cardiovascular risk reduction with icosapent ethyl for hypertriglyceridaemia
Learning module instructions
This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning). Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value. After you have successfully completed the test you will be able to download your certificate.
References
- NIH. High blood triglycerides. 2023. Available at: https://www.nhlbi.nih.gov/health/high-blood-triglycerides#:~:text=Triglycerides%20are%20a%20type%20of,and%20other%20fats%20you%20eat (accessed March 2024)
- NICE. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides [TA805] 2022. Available at: https://www.nice.org.uk/guidance/ta805. (accessed March 2024)
- Padda IS et al. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK592399/ (accessed March 2024)
- Heart UK. Type 3 hyperlipidaemia. Available at: https://www.heartuk.org.uk/genetic-conditions/type-3-hyperlipidaemia (accessed March 2024)
- Heart UK. Triglycerides. 2024. Available at: https://www.heartuk.org.uk/cholesterol/triglycerides (accessed March 2024)
- Bhatt DL et al. N Engl J Med 2019;380:11–22
- Benuck I et al. Endotext [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK395574/ (accessed March 2024)
